ArticleInternational journal of nanomedicine2021
p53 Promoted Ferroptosis in Ovarian Cancer Cells Treated with Human Serum Incubated-Superparamagnetic Iron Oxides.
Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 87 citations in OpenAlex.
- Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure.Journal of translational medicine · 2026Review
- Interconnected cell death pathways: central mechanisms and therapeutic targets in impaired follicular development of polycystic ovary syndrome.Journal of ovarian research · 2026Review
- Advances in ferroptosis research in ovarian cancer: molecular mechanisms and therapeutic perspectives.American journal of cancer research · 2026Review
- Targeting Aging and Diseases Associated with Ferroptosis and Senescence Through Modulation of Iron, Oxidative Stress and Lipid Peroxidation.Antioxidants (Basel, Switzerland) · 2025Review
- The role of ferroptosis in liver injury after cold ischemia-reperfusion in rats with autologous orthotopic liver transplantation.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Article
- The Role of Ferroptosis in Women's Health and Diseases.MedComm · 2025Review
- The intersection of ferroptosis and non-coding RNAs: a novel approach to ovarian cancer.European journal of medical research · 2025Review
- Multifunctional Nanomaterials: Recent Advancements in Cancer Therapeutics and Vaccines.Indian journal of microbiology · 2025Article
- The natural compound n-butylidenephthalide suppresses type II ovarian cancer cell growth by inducing ferroptosis.International journal of medical sciences · 2025Article
- Targeting ferroptosis: a promising avenue for ovarian cancer treatment.Frontiers in immunology · 2025Review
- Silencing KPNA2 Promotes Ferroptosis in Laryngeal Cancer by Activating the FoxO Signaling Pathway.Biochemical genetics · 2024Article
- The recent advancements of ferroptosis of gynecological cancer.Cancer cell international · 2024Review
- Magnetic nanoparticles and possible synergies with cold atmospheric plasma for cancer treatment.RSC advances · 2024Review
- Recent trends in preparation and biomedical applications of iron oxide nanoparticles.Journal of nanobiotechnology · 2024Review
- Unraveling the Molecular Regulation of Ferroptosis in Respiratory Diseases.Journal of inflammation research · 2024Review
- Ferroptosis: mechanism, immunotherapy and role in ovarian cancer.Frontiers in immunology · 2024Review
- Ferroptosis, Metabolic Rewiring, and Endometrial Cancer.International journal of molecular sciences · 2023Review
- Nano-modulators with the function of disrupting mitochondrial CaJournal of nanobiotechnology · 2023Article
- Ferroptosis in epithelial ovarian cancer: a burgeoning target with extraordinary therapeutic potential.Cell death discovery · 2023Review
- Ferroptosis and the bidirectional regulatory factor p53.Cell death discovery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
methodsIn this study, we used MTT assays to demonstrate that a combination of SPIO-Serum and wild-type p53 overexpression can reduce ovarian cancer cell viability
resultsSPIO-Serum effectively induced lipid peroxidation and generated abundant toxic ROS. It also facilitated the downregulation of GPX4 and xCT, ultimately resulting in iron-dependent oxidative death. These effects could be reversed by iron chelator DFO and lipid peroxidation inhibitor Fer-1. SPIO-Serum treatment disrupted intracellular iron homeostasis by regulating iron uptake and the cells presented with missing mitochondrial cristae and ruptured outer mitochondrial membranes. Moreover, we were able to show that p53 contributed to SPIO-Serum-induced ferroptosis in ovarian cancer cells.
conclusionSPIO-Serum induced ferroptosis and overexpressed p53 contributed to ferroptosis in ovarian cancer cells. Our data provide a theoretical basis for ferroptosis as a novel cell death phenotype induced by nanomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.